MARK4 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the MARK4 gene in the Raji B lymphocyte line. These cells, generated through CRISPR/Cas9-mediated gene disruption, afford a loss-of-function model without requiring clonal expansion, maintaining population diversity. The polyclonal format facilitates robust functional studies of MARK4 in a reproducible lymphoblastoid background, enabling analysis of its roles in microtubule regulation, signaling, and disease-relevant processes.
The Raji cell line is an EBV-positive B lymphoblast line derived from a Burkitt??s lymphoma patient. These suspension-adapted cells constitutively express CD19, CD20, and other B-cell surface antigens, and their transformed phenotype is driven by EBV latency programs. Raji cells are extensively used to model B-cell malignancies, immune signaling, and lymphomagenesis, providing a clinically relevant backdrop for interrogating MARK4 function in the context of oncogenic signaling and cytoskeletal regulation.
MARK4 encodes a microtubule affinity-regulating kinase that phosphorylates tau, MAP2, and MAP4, leading to microtubule destabilization. Activated by LKB1 and AMPK, it also responds to Wnt ligands and cellular energy stress. Downstream, MARK4 phosphorylates Raptor to inhibit mTORC1 and phosphorylates Cdc25C to control G2/M transition. The kinase interacts with 14-3-3 proteins, ??-tubulin, DVL2, USP9X, and PP2A, integrating signals from metabolic sensing, cell polarity, and growth factor pathways. Thus, MARK4 sits at the nexus of the LKB1/AMPK, mTOR, and Wnt/planar cell polarity networks.
In Raji lymphoma cells, MARK4 knockout disrupts its regulatory influence on microtubule dynamics and mTOR signaling, allowing dissection of its contributions to oncogenic phenotypes. Since Burkitt??s lymphoma is characterized by rapid proliferation and active cell cycle machinery, loss of MARK4 function may impact mitotic progression and apoptotic thresholds. The model also permits studies of EBV manipulation of host cytoskeletal and metabolic pathways, as MARK4-dependent phosphorylation of tau and MAPs influences microtubule stability, potentially affecting immune synapse formation and B-cell receptor trafficking.
These polyclonal knockout cells support applications in cancer signaling, Alzheimer??s disease tau research, mTOR pathway analysis, cell cycle studies, and metabolic stress investigation. Representative assays include Western blotting (MARK4, phospho-tau Ser262, phospho-S6K), immunofluorescence for microtubule organization, flow cytometry for cell cycle and apoptosis, proliferation assays, and co-immunoprecipitation for protein interactions. The model is also suitable for kinase inhibitor screening. For additional information or technical consultation, please contact Ascent Research.
